Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation.
Tissue factor, which is expressed in vascular lesions, increases thrombin production, blood coagulation, and smooth muscle cell proliferation. We demonstrate that oxidized low-density lipoprotein (LDL) induces surface tissue factor pathway activity (ie, activity of the tissue factor:factor VIIa complex) on human and rat smooth muscle cells. Tissue factor messenger RNA (mRNA) was induced by oxidized LDL or native LDL; however, native LDL did not markedly increase tissue factor activity. We hypothesized that oxidized LDL mediated the activation of the tissue factor pathway via an oxidant-dependent mechanism, because antioxidants blocked the enhanced tissue factor pathway activity by oxidized LDL, but not the increased mRNA or protein induction. We separated total lipid extracts of oxidized LDL using high-performance liquid chromatography (HPLC). This yielded 2 major peaks that induced tissue factor activity. Of the known oxysterols contained in the first peak, 7alpha- or 7beta-hydroxy or 7-ketocholesterol had no effect on tissue factor pathway activity; however, 7beta-hydroperoxycholesterol increased tissue factor pathway activity without induction of tissue factor mRNA. Tertiary butyl hydroperoxide also increased tissue factor pathway activity, suggesting that lipid hydroperoxides, some of which exist in atherosclerotic lesions, activate the tissue factor pathway. We speculate that thrombin production could be elevated via a mechanism involving peroxidation of cellular lipids, contributing to arterial thrombosis after plaque rupture. Our data suggest a mechanism by which antioxidants may offer a clinical benefit in acute coronary syndrome and restenosis.
Penn
M S
MS
Departments of Cardiology, Cell Biology, and Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Cui
M Z
MZ
Winokur
A L
AL
Bethea
J
J
Hamilton
T A
TA
DiCorleto
P E
PE
Chisolm
G M
GM
D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001011:Aorta / Q000502:physiology; D001393:Azoles / Q000494:pharmacology; D002478:Cells, Cultured; D003676:Deferoxamine / Q000494:pharmacology; D006801:Humans; D054833:Isoindoles; D007700:Kinetics; D015227:Lipid Peroxidation; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D016566:Organoselenium Compounds / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013925:Thromboplastin / Q000235:genetics* / Q000502:physiology; D017971:Tin Compounds / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects
D000975:Antioxidants; D001393:Azoles; D054833:Isoindoles; D008077:Lipoproteins, LDL; D016566:Organoselenium Compounds; D017971:Tin Compounds; C099252:oxidized low density lipoprotein; C023599:stannous chloride; C042986:ebselen; D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; D013925:Thromboplastin; D003676:Deferoxamine